European Medicines Evaluation Agency Approves Boehringer Ingelheim Corporation's TWYNSTA(R) a New Single Pill Combination that Delivers Powerful and Consistent Blood Pressure Reductions Throughout 24 Hours  
10/12/2010 10:35:12 AM

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA®. TWYNSTA® is indicated for the treatment of hypertension in adults whose blood pressure is not adequately controlled on amlodipine or as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets containing the same component doses.